Single-Pill, Triple Antihypertensive Therapy in Rural Sub-Saharan Africa: Preliminary Experience.

Amlodipine Arterial hypertension Blood pressure Hydrochlothiazide Olmesartan Polypill Rural Single-pill combination Sub-Saharan Africa

Journal

Cardiology and therapy
ISSN: 2193-8261
Titre abrégé: Cardiol Ther
Pays: England
ID NLM: 101634495

Informations de publication

Date de publication:
12 Feb 2024
Historique:
received: 04 12 2023
accepted: 22 01 2024
medline: 12 2 2024
pubmed: 12 2 2024
entrez: 12 2 2024
Statut: aheadofprint

Résumé

Worldwide, arterial hypertension is the foremost preventable and modifiable cardiovascular risk factor. In addition to lifestyle changes, recent international guidelines recommend single-pill, low-dose combinations as initial treatment strategy. We investigated whether this approach is feasible in a rural sub-Saharan Africa setting. Diagnosis of hypertension was established over three sets of blood pressure measurements, performed according to the European Society of Hypertension recommendations by trained personnel, using a validated, automated, oscillometric device OMRON M7 IT-HEM-7322-E. In 98 individuals with arterial hypertension, a once-daily, single-pill combination of olmesartan, amlodipine, and hydrochlorothiazide was prescribed at an appropriate dose. Patients were instructed on its administration and potential side effects and encouraged towards lifestyle modifications. The treatment regimen was adjusted, if needed, at each outpatient clinic scheduled after 4, 8, 12, and 16 weeks. Seventy-nine patients (aged 61 [53-70] years; median and interquartile range) strictly adhered to the treatment schedule, while 19 individuals (70 [65-80] years) dropped out. Blood pressure was < 140/90 mmHg after 4 weeks in 44 (56%), after 8 weeks in 62 (78%), after 12 weeks in 69 (87%), and after 16 weeks in 74 (94%) participants. Excellent tolerance was reported. These results provide real-life evidence that hypertension management with a once-daily, single-pill combination of olmesartan, amlodipine, and hydrochlorothiazide as initial treatment is feasible and effective also in a rural sub-Saharan setting. Single-pill combinations should be made available also in rural and remote areas in low- and middle-income countries as a reliable first-line treatment strategy.

Identifiants

pubmed: 38345713
doi: 10.1007/s40119-024-00358-5
pii: 10.1007/s40119-024-00358-5
doi:

Types de publication

Journal Article

Langues

eng

Informations de copyright

© 2024. The Author(s).

Références

Parati G, Lackland DT, Campbell NRC, et al. How to improve awareness, treatment, and control of hypertension in Africa, and how to reduce its consequences: a call to action from the world hypertension league. Hypertension. 2022;79:1949–61.
doi: 10.1161/HYPERTENSIONAHA.121.18884 pubmed: 35638381
Wang N, Rueter P, Atkins E, et al. Efficacy and safety of low-dose triple and quadruple combination pills vs monotherapy, usual care, or placebo for the initial management of hypertension: a systematic review and meta-analysis. JAMA Cardiol. 2023;8(6):606–11.
doi: 10.1001/jamacardio.2023.0720 pubmed: 37099314
Global report on hypertension: the race against a silent killer. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO.
Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension. 2021;77(2):692–705.
doi: 10.1161/HYPERTENSIONAHA.120.15781 pubmed: 33390044
Volpe M, Tocci G. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic. Vasc Health Risk Manag. 2012;8:371–80.
doi: 10.2147/VHRM.S28359 pubmed: 22745561 pmcid: 3383291
Muggli F, Parati G, Suter P, et al. Blood pressure in a population of a rural area of Rwanda: preliminary data. J Hypertens. 2021;39(Suppl 1): e400.
doi: 10.1097/01.hjh.0000749228.89530.93
Mancia G, Kreutz R, Brunström M, et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. 2023;41:1874–2071.
doi: 10.1097/HJH.0000000000003480 pubmed: 37345492
Adler C, Ellert U, Neuhauser HK. Disagreement of the two oscillometric blood pressure measurement devices, Datascope accutorr plus and Omron HEM-705CP II, and bidirectional conversion of blood pressure values. Blood Press Monit. 2014;19:109–17.
doi: 10.1097/MBP.0000000000000037 pubmed: 24583967
Bilo G, Sala O, Perego C, et al. Impact of cuff positioning on blood pressure measurement accuracy: may a specially designed cuff make a difference? Hypertens Res. 2017;40:573–80.
doi: 10.1038/hr.2016.184 pubmed: 28077860 pmcid: 5506235
Brown GW, Hayden GF. Nonparametric methods. Clinical applications. Clin Pediatr (Phila). 1985;24:490–8.
doi: 10.1177/000992288502400905 pubmed: 4017399
Poitras G. More on the correct use of omnibus tests for normality. Econ Lett. 2006;90:304–9.
doi: 10.1016/j.econlet.2005.08.016
Bahna SL, McLarty JW. Data presentation. Ann Allergy Asthma Immunol. 2009;103:S15–21.
doi: 10.1016/S1081-1206(10)60816-2 pubmed: 19891282
Burnier M, Redon J, Volpe M. Single-pill combination with three antihypertensive agents to improve blood pressure control in hypertension: focus on olmesartan-based combinations. High Blood Press Cardiovasc Prev. 2023;30:109–21.
doi: 10.1007/s40292-023-00563-8 pubmed: 36696054 pmcid: 10090015
Kjeldsen SE, Messerli FH, Chiang CE, Meredith PA, Liu L. Are fixed-dose combination antihypertensives suitable as first-line therapy? Curr Med Res Opin. 2012;28(10):1685–97.
doi: 10.1185/03007995.2012.729505 pubmed: 22978777
Neutel JM, Smith DH. Hypertension management: rationale for triple therapy based on mechanisms of action. Cardiovasc Ther. 2013;31(5):251–8.
doi: 10.1111/1755-5922.12015 pubmed: 23121769
Rea F, Corrao G, Merlino L, Mancia G. Initial antihypertensive treatment strategies and therapeutic inertia. Hypertension. 2018;72(4):846–53.
doi: 10.1161/HYPERTENSIONAHA.118.11308 pubmed: 30354712
Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427.
doi: 10.1136/bmj.326.7404.1427 pubmed: 12829555 pmcid: 162261
Albanna AS, Smith BM, Cowan D, Menzies D. Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis. Eur Respir J. 2013;42(3):721–32.
doi: 10.1183/09031936.00180612 pubmed: 23314904
Cutrell J, Bedimo R. Single-tablet regimens in the treatment of HIV-1 infection. Fed Pract. 2016;33(Suppl 3):24S-30S.
pubmed: 30766212 pmcid: 6375416
Alven S, Aderibigbe B. Combination therapy strategies for the treatment of malaria. Molecules. 2019;24(19):3601.
doi: 10.3390/molecules24193601 pubmed: 31591293 pmcid: 6804225
Sonderup MW, Afihene M, Ally R, et al. Gastroenterology and hepatology association of sub-Saharan Africa (GHASSA). Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030. Lancet Gastroenterol Hepatol. 2017;2(12):910–9.
doi: 10.1016/S2468-1253(17)30249-2 pubmed: 29132760
Ajayi AAL, Ajayi OE. Pathophysiologically based antihypertensive pharmacotherapeutics rationality, efficacy and safety in Sub Saharan African nations - a review. Int J Cardiol Cardiovasc Risk Prev. 2021;11: 200111.
pubmed: 34825245 pmcid: 8605193
Bruyn E, Nguyen L, Schutte AE, Murphy A, Perel P, Webster R. Implementing single-pill combination therapy for hypertension: a scoping review of key health system requirements in 30 low- and middle-income countries. Glob Heart. 2022;17(1):6.
doi: 10.5334/gh.1087 pubmed: 35174047 pmcid: 8796691
Saxena PR. Interaction between the renin–angiotensin–aldosterone and sympathetic nervous systems. J Cardiovasc Pharmacol. 1992;19(Suppl 6):S80–8.
doi: 10.1097/00005344-199219006-00013 pubmed: 1382170
Choudhry NK, Kronish IM, Vongpatanasin W, et al. American Heart Association council on hypertension; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Medication adherence and blood pressure control: a scientific statement from the American Heart Association. Hypertension. 2022;79(1):e1–14.
doi: 10.1161/HYP.0000000000000203 pubmed: 34615363
Sibomana JP, McNamara RL, Walker TD. Patient, clinician and logistic barriers to blood pressure control among adult hypertensives in rural district hospitals in Rwanda: a cross-sectional study. BMC Cardiovasc Disord. 2019;19(1):231.
doi: 10.1186/s12872-019-1203-3 pubmed: 31638907 pmcid: 6805529
Ataklte F, Erqou S, Kaptoge S, Taye B, Echouffo-Tcheugui JB, Kengne AP. Burden of undiagnosed hypertension in sub-Saharan Africa: a systematic review and meta-analysis. Hypertension. 2015;65:291–8.
doi: 10.1161/HYPERTENSIONAHA.114.04394 pubmed: 25385758
Turé R, Damasceno A, Djicó M, Lunet N. Prevalence, awareness, treatment, and control of hypertension in Bissau, Western Africa. J Clin Hypertens (Greenwich). 2022;24:358–61.
doi: 10.1111/jch.14443 pubmed: 35172025

Auteurs

Clara Stroppa (C)

School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
Family Medicine Institute, Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland.

Isabella Hunjan (I)

School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
Family Medicine Institute, Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland.

Alice Umulisa (A)

Health Care Centre of Nyamyumba, Nyamyumba, District of Nyaruguru, Rwanda.

Benitha Irebe (B)

Health Care Centre of Nyamyumba, Nyamyumba, District of Nyaruguru, Rwanda.

Gianfranco Parati (G)

School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
Department of Cardiovascular, Neural and Metabolic Sciences, Istituto Auxologico Italiano IRCCS, San Luca Hospital, Milan, Italy.

Mario G Bianchetti (MG)

Family Medicine Institute, Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland.

Bienvenu Muvunyi (B)

Medical Specialized Services, King Faisal Hospital, Kigali, Rwanda.

Evariste Ntaganda (E)

Cardiovascular Diseases Unit, Non-Communicable Diseases Division, Rwanda Biomedical Center, Kigali, Rwanda.

Vincent Sinabubaraga (V)

District Hospital, Munini, Rwanda.

Dragana Radovanovic (D)

Family Medicine Institute, Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland.

Sebastiano A G Lava (SAG)

Pediatric Cardiology Unit, Department of Pediatrics, Centre Hospitalier Universitaire Vaudois, and University of Lausanne, 1011, Lausanne, Switzerland. webmaster@sebastianolava.ch.
Clinical Pharmacology & Therapeutics Group, University College London, London, UK. webmaster@sebastianolava.ch.

Franco Muggli (F)

Family Medicine Institute, Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland.

Classifications MeSH